This effect was associated with increased prostaglandin (PG) E2 and prostacyclin (PGI2) releases.
Such an effect was associated with significant decrease of AgNOR and PCNA-labeling index.
For PFS, a protective effect was associated with ISS I, mutation of TRAF3, and gain/amplification of 7q, 15q, and 19q.
This effect was associated with inactivation of Wnt/β-catenin pathway in differentiating HFSC by both DPC-conditioned media.
This effect was associated with alterations in phosphotyrosine profile and with a marked decrease of ERK and NJK kinase activation.
This effect was associated with a reduced expression of several proteinases.
The size effect was associated to the fatigue behavior as well.
Patient satisfaction was uniformly associated with expectations being met, but only satisfaction with treatment effect was associated with lower pain and disability scores.
The latter effect was associated with significant upregulation of the expression of the myogenic regulatory factors MyoD and Myogenin and certain genes involved in cell cycle regulation.
This effect was associated with the inhibition of multiple kinase pathways including MAPK, PI3K/AKT, and NF-κB signaling pathways.
FTS effect was associated with significantly inhibition of both MMP-2 and MMP-9 activities.
